rs200076893
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM1PP3
The NM_000249.4(MLH1):c.376T>A(p.Tyr126Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000521 in 1,613,682 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y126H) has been classified as Uncertain significance.
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.376T>A | p.Tyr126Asn | missense_variant | 4/19 | ENST00000231790.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.376T>A | p.Tyr126Asn | missense_variant | 4/19 | 1 | NM_000249.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152244Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251404Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135864
GnomAD4 exome AF: 0.0000534 AC: 78AN: 1461320Hom.: 0 Cov.: 30 AF XY: 0.0000481 AC XY: 35AN XY: 727014
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152362Hom.: 0 Cov.: 33 AF XY: 0.0000268 AC XY: 2AN XY: 74508
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 15, 2023 | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Sep 30, 2016 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jul 02, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 22, 2024 | Observed in individuals with colorectal cancer, breast cancer, endometrial cancer, and/or polyps (PMID: 24383517, 30998989, 35475445, 35430768); Published functional studies demonstrate no damaging effect: variant classified as not pathogenic based on cell survival assay (PMID: 30998989); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24383517, 27527004, 22290698, 18561205, 26333163, 26659599, 22788692, 16451135, 22753075, 35430768, 35475445, 30998989) - |
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Feb 15, 2023 | This missense variant replaces tyrosine with asparagine at codon 126 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A functional study has shown that this variant does not affect MLH1 protein function in a methylation tolerance-based assay (PMID: 30998989). This variant has been observed in an individual affected with colorectal cancer and a Lynch syndrome family (PMID: 18561205, 24383517). This variant has been identified in 11/282808 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 03, 2024 | The p.Y126N variant (also known as c.376T>A), located in coding exon 4 of the MLH1 gene, results from a T to A substitution at nucleotide position 376. The tyrosine at codon 126 is replaced by asparagine, an amino acid with dissimilar properties. This alteration has been reported as an uncertain variant in a proband diagnosed with colon cancer at age <50 years, whose family history met Amsterdam II criteria. In addition, the proband's tumor was MSI-H and demonstrated loss of MLH1 by immunohistochemistry (IHC; Stigliano V et al. J Exp Clin Cancer Res. 2014 Jan; 33:1). This alteration was reported in another proband with a personal history of endometrial cancer, undergoing genetic testing due to a clinical suspicion of Lynch syndrome. The proband's tumor was MSI-H and demonstrated loss of MLH1 and PMS2 by IHC (Liccardo R et al. Int J Mol Med, 2022 Jun;49:). However, this variant has been detected in multiple individuals with no reported features of Lynch syndrome. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jun 08, 2022 | - - |
Lynch syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 01, 2023 | This missense variant replaces tyrosine with asparagine at codon 126 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A functional study has shown that this variant does not affect MLH1 protein function in a methylation tolerance-based assay (PMID: 30998989). This variant has been observed in an individual affected with colorectal cancer and a Lynch syndrome family (PMID: 18561205, 24383517). This variant has been identified in 11/282808 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change replaces tyrosine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 126 of the MLH1 protein (p.Tyr126Asn). This variant is present in population databases (rs200076893, gnomAD 0.009%). This missense change has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 18561205, 24383517, 30998989). ClinVar contains an entry for this variant (Variation ID: 90184). An algorithm developed specifically for the MLH1 gene suggests that this missense change is likely to be deleterious (PMID: 22290698). Experimental studies have shown that this missense change does not substantially affect MLH1 function (PMID: 30998989). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at